文献速递生殖医学

子宫内膜BCL6检测预测体外受精结局:一项队列研究

Endometrial BCL6 testing for the prediction of in vitro fertilization outcomes: a cohort study.
PubMed 文献 · Fertil Steril · 2017-11-07

该前瞻性队列研究在不孕年限超过1年的不明原因不孕女性中,于黄体中期活检检测子宫内膜BCL6表达,并比较BCL6阳性与阴性者的体外受精结局。BCL6低表达组临床妊娠率和活产率均显著高于BCL6异常高表达组。

要点

  • BCL6异常以组织学评分>1.4定义。
  • 低表达组临床妊娠率64.7%,异常高表达组17.3%。
  • 低表达组活产率58.8%,异常高表达组11.5%。

核心结论

  • 在不明原因不孕女性中,BCL6异常表达(组织学评分>1.4)与体外受精周期不良生殖结局强烈相关。

研究设计与样本

  • 前瞻性队列研究,在大学附属不孕门诊开展。
  • 研究对象为不明原因不孕超过1年的女性,接受黄体中期LH定时子宫内膜活检检测BCL6,并完成体外受精周期及胚胎移植。

主要发现

  • BCL6低表达组临床妊娠率11/17(64.7%,95%CI 41.3-82.6),BCL6异常高表达组9/52(17.3%,95%CI 9.3-30.8)。
  • BCL6低表达组相对风险为0.267(95%CI 0.13-0.53;P=.0004),绝对获益47.4%(95%CI 22.5-72.0)。
  • BCL6低表达组活产率10/17(58.8%,95%CI 36.0-78.4),BCL6异常高表达组6/52(11.5%,95%CI 5.4-23.0)。
  • BCL6低表达组活产相对风险为0.19(95%CI 0.08-0.45;P=.0002),绝对获益47.3%(95%CI 21.8-67.8)。
  • BCL6正常与异常者及是否妊娠者特征相似。

关键数值与推荐

  • BCL6异常结果定义为组织学评分>1.4。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate endometrial BCL6 expression as a prognostic biomarker for IVF outcome in women with unexplained infertility (UI) before ET. DESIGN: Prospective cohort study. SETTING: University-associated infertility clinic. PATIENT(S): Women with UI for >1 year. INTERVENTION(S): We studied women with UI who underwent testing for endometrial BCL6, in an LH-timed midluteal phase biopsy and completed an IVF cycle and ET. MAIN OUTCOME MEASURE(S): Clinical pregnancy rate (PR) and live birth rate per transfer was compared for women positive or negative for BCL6 expression. An abnormal BCL6 result was defined by an histologic score (>1.4). RESULT(S): Women with normal and abnormal BCL6 and those who conceived or not had similar characteristics. Women with low levels of BCL6 expression had a significantly higher clinical PR (11/17; 64.7%; 95% confidence interval [CI] 41.3-82.6) compared with women with abnormal (high) BCL6 expression (9/52; 17.3%; 95% CI 9.3-30.8). These results yield a relative risk of 0.267 (95% CI 0.13-0.53; P=.0004) for those with normal BCL6 expression, an absolute benefit of 47.4% (95% CI 22.5-72.0). Live birth rate was also significantly higher in women with low BCL6 expression (10/17; 58.8%; 95% CI 36.0-78.4) compared with women with abnormal BCL6 expression (6/52; 11.5%; 95% CI 5.4-23.0). The relative risk was 0.19 (95% CI 0.08-0.45; P=.0002), yielding an absolute benefit of 47.3% (95% CI 21.8-67.8). CONCLUSION(S): Aberrant BCL6 expression (histologic score, >1.4) was strongly associated with poor reproductive outcomes in IVF cycles in women with UI.

来源:Fertil Steril,查看原文。版权归原作者所有。

引用

  1. Almquist LD, Likes CE, Stone B, et al. Endometrial BCL6 testing for the prediction of in vitro fertilization outcomes: a cohort study. Fertil Steril. 2017. PMID: 29126613. doi:10.1016/j.fertnstert.2017.09.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。